Endocrine Abstracts

Resistance to endocrine treatment develops with time in virtually all patients with metastatic breast cancer (BC), and eventually most of them are treated with chemotheray. Our group and others discovered a group of mutations in the ligand binding domain (LBD) of the estrogen receptor (ER), that are the direct cause of resistance in ~40% of the patients. The most common mutations are Y537S and D538G ER. Clinical data indicate an association between those ER mutations worse pro...

Background: Klotho is a 1012 amino acids transmembrane protein, composed of two internal repeats, KL1 and KL2, that can be cleaved, shed and act as a circulating hormone. Klotho regulates several pathways, including fibroblast growth factor 23 (FGF23), Wnt-β/catenin and the cation channels TRPV and TRPC. Our group and other labs identified klotho as a potent tumor suppressor in breast and pancreatic cancers and that KL1 domain is responsible for this activity. Yet, the me...

Introduction: Type 2 diabetes mellitus (T2DM) and cancer commonly occur together, either because of direct association or merely as both diseases are common among the elderly. The presence of either T2DM itself, or its treatment may affect cancer progression outcomes and response to cancer therapy. Immune-checkpoint inhibitors (ICIs) have become the cornerstone of treatment of several malignancies, including non-small cell lung cancer (NSCLC). As T2DM has been shown to suppres...